| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
56.72
|
|
2
|
Standardisation of spirometry.
|
Eur Respir J
|
2005
|
48.20
|
|
3
|
A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
|
N Engl J Med
|
2008
|
17.19
|
|
4
|
Development and first validation of the COPD Assessment Test.
|
Eur Respir J
|
2009
|
8.06
|
|
5
|
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
|
Ann Intern Med
|
2007
|
5.51
|
|
6
|
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes.
|
Chest
|
1984
|
5.19
|
|
7
|
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
|
N Engl J Med
|
2016
|
4.51
|
|
8
|
Hospitalizations and mortality in the Lung Health Study.
|
Am J Respir Crit Care Med
|
2002
|
4.11
|
|
9
|
COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity.
|
Chest
|
2002
|
3.34
|
|
10
|
Minimal clinically important differences in COPD lung function.
|
COPD
|
2005
|
3.00
|
|
11
|
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
|
Thorax
|
2010
|
2.79
|
|
12
|
Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study.
|
Chest
|
2009
|
2.65
|
|
13
|
Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies.
|
Thorax
|
2011
|
2.59
|
|
14
|
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.
|
Cochrane Database Syst Rev
|
2014
|
2.41
|
|
15
|
Tiotropium versus placebo for chronic obstructive pulmonary disease.
|
Cochrane Database Syst Rev
|
2012
|
2.21
|
|
16
|
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.
|
Chest
|
2009
|
2.20
|
|
17
|
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
|
Lancet
|
2016
|
2.19
|
|
18
|
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
|
Eur Respir J
|
2009
|
2.11
|
|
19
|
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
|
Eur Respir J
|
2012
|
1.98
|
|
20
|
The efficiency of simulation-based multiple comparisons.
|
Biometrics
|
1987
|
1.91
|
|
21
|
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.
|
Respir Res
|
2011
|
1.89
|
|
22
|
The safety of tiotropium--the FDA's conclusions.
|
N Engl J Med
|
2010
|
1.85
|
|
23
|
Minimal important difference of the transition dyspnoea index in a multinational clinical trial.
|
Eur Respir J
|
2003
|
1.84
|
|
24
|
Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.
|
Chest
|
2005
|
1.83
|
|
25
|
The local side effects of inhaled corticosteroids: current understanding and review of the literature.
|
Chest
|
2004
|
1.76
|
|
26
|
Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis.
|
Ann Allergy Asthma Immunol
|
2007
|
1.74
|
|
27
|
Inhaled corticosteroids and the risks of diabetes onset and progression.
|
Am J Med
|
2010
|
1.66
|
|
28
|
Inhaled corticosteroids for stable chronic obstructive pulmonary disease.
|
Cochrane Database Syst Rev
|
2007
|
1.58
|
|
29
|
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
|
Thorax
|
2015
|
1.55
|
|
30
|
Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores.
|
BMC Pulm Med
|
2011
|
1.54
|
|
31
|
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
|
Int J Chron Obstruct Pulmon Dis
|
2012
|
1.52
|
|
32
|
FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
|
Am J Respir Crit Care Med
|
2015
|
1.51
|
|
33
|
Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis.
|
Thorax
|
2012
|
1.48
|
|
34
|
Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
|
Thorax
|
2008
|
1.47
|
|
35
|
Relationship between salivary flow rates and Candida counts in subjects with xerostomia.
|
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
|
2002
|
1.45
|
|
36
|
Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010.
|
Respir Res
|
2013
|
1.13
|
|
37
|
Use of inhaled and oral corticosteroids and the long-term risk of cataract.
|
Ophthalmology
|
2009
|
1.13
|
|
38
|
Smoking cessation and COPD.
|
Eur Respir Rev
|
2013
|
1.09
|
|
39
|
Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.
|
Drugs
|
2012
|
1.09
|
|
40
|
Long-acting beta2-agonists for chronic obstructive pulmonary disease.
|
Cochrane Database Syst Rev
|
2013
|
1.07
|
|
41
|
Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
|
Respir Med
|
2011
|
1.05
|
|
42
|
Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population.
|
Am Rev Respir Dis
|
1991
|
1.02
|
|
43
|
Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients.
|
Int J Chron Obstruct Pulmon Dis
|
2008
|
1.01
|
|
44
|
Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis.
|
Int J Chron Obstruct Pulmon Dis
|
2013
|
1.01
|
|
45
|
Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials.
|
Respir Res
|
2014
|
0.99
|
|
46
|
Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary.
|
Thorax
|
2014
|
0.98
|
|
47
|
Inhalational and topical steroids, and oral candidosis: a mini review.
|
Oral Dis
|
2001
|
0.95
|
|
48
|
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
|
Int J Chron Obstruct Pulmon Dis
|
2012
|
0.89
|
|
49
|
Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.
|
BMC Pulm Med
|
2014
|
0.89
|
|
50
|
Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II.
|
Chest
|
2004
|
0.89
|
|
51
|
Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler.
|
Eur Respir J
|
2002
|
0.87
|
|
52
|
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.
|
COPD
|
2015
|
0.87
|
|
53
|
Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD.
|
Chest
|
2001
|
0.86
|
|
54
|
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.
|
Ann Am Thorac Soc
|
2015
|
0.85
|
|
55
|
A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
|
BMC Pulm Med
|
2012
|
0.85
|
|
56
|
Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
|
Pulm Pharmacol Ther
|
2014
|
0.82
|
|
57
|
Safety and tolerability of inhalational anticholinergics in COPD.
|
Drug Healthc Patient Saf
|
2013
|
0.82
|
|
58
|
Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database.
|
Int J Chron Obstruct Pulmon Dis
|
2011
|
0.81
|
|
59
|
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
|
COPD
|
2015
|
0.81
|
|
60
|
Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
|
Int J Chron Obstruct Pulmon Dis
|
2012
|
0.80
|
|
61
|
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
|
Int J Chron Obstruct Pulmon Dis
|
2016
|
0.78
|
|
62
|
Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
|
Lancet Respir Med
|
2016
|
0.76
|
|
63
|
Smoking cessation for people with chronic obstructive pulmonary disease.
|
Cochrane Database Syst Rev
|
2016
|
0.76
|
|
64
|
Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
|
Respir Med
|
2016
|
0.75
|
|
65
|
Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study.
|
Chronic Obstr Pulm Dis
|
2016
|
0.75
|